Clinical Study of SHR-A1921 or SHR-A2009 in Previously Treated Advanced NSCLC
This study is an open-label Phase II clinical trial to evaluate the safety and efficacy of SHR-A1921 or SHR-A2009 in patients with advanced NSCLC who progressed after standard therapy.
NSCLC
DRUG: SHR-A2009|DRUG: SHR-A1921
Overall response rate (ORR), Assessed by Investigator According to RECIST v1.1, up to 12 months
Progression-free survival (PFS), Assessed by Investigator According to RECIST v1.1, up to 12 months|overall survival (OS), OS is the time from the date of first dose until the date of death by any cause., up to 24 months|Duration of response(DoR ), Assessed by Investigator According to RECIST v1.1, up to 12 months|Disease control rate (DCR), Assessed by Investigator According to RECIST v1.1, up to 12 months|Time to Response (TTR), Assessed by Investigator According to RECIST v1.1, up to 12 months|The incidence and severity of adverse events (AEs), Rated based on CTCAE V5.0, from Day1 to 90 days after last dose
This study is an open-label Phase II clinical trial to evaluate the safety and efficacy of SHR-A1921 or SHR-A2009 in patients with advanced NSCLC who progressed after standard therapy.